Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
07 mars 2023 09h19 HE
|
Aclarion, Inc.
Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield,...
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
15 févr. 2023 07h00 HE
|
Aclarion, Inc.
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a...
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
31 janv. 2023 10h01 HE
|
Aclarion, Inc.
Director of Endoscopic Spine Surgery at the University of Miami Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:...
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
17 janv. 2023 08h29 HE
|
Aclarion, Inc.
Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
22 déc. 2022 10h36 HE
|
Aclarion, Inc.
Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
21 déc. 2022 10h23 HE
|
Aclarion, Inc.
Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO, Dec. 21,...
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
19 déc. 2022 08h33 HE
|
Aclarion, Inc.
Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer...
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
01 déc. 2022 09h41 HE
|
Aclarion, Inc.
Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP...